Medical Use
Farydak is a histone deacetylase inhibitor used in combination with bortezomib and dexamethasone to treat multiple myeloma in patients who have undergone at least two prior treatments, including bortezomib and an immunomodulatory agent.
Recommended Dosage:
- Farydak: Start with 20 mg capsules taken orally every other day at the same time, with or without food, for three doses per week during Weeks 1 and 2 of each 21-day cycle, up to 8 cycles. If patients benefit clinically and do not experience severe or significant toxicity, consider continuing for an additional 8 cycles, making the total treatment duration up to 16 cycles (48 weeks).
- Bortezomib: Administer 1.3 mg/m² as an injection.
- Dexamethasone: Take 20 mg orally on scheduled days, with food.
Missed Dose:
- If a dose is missed, it can be taken up to 12 hours after the scheduled time. If vomiting occurs, do not repeat the dose; instead, take the next scheduled dose as usual.
Warning & Precautions
Severe Diarrhea: Patients treated with panobinostat 20 mg capsules may experience severe diarrhea. It’s important to monitor hydration status and electrolyte levels, including magnesium, potassium, and phosphate, on a weekly basis during therapy. Correct any imbalances to prevent dehydration and electrolyte disturbances. Start anti-diarrheal medication at the first sign of diarrhea.
Cardiac Issues: Severe and potentially fatal cardiac ischemic events, arrhythmias, and ECG changes have been reported in patients taking panobinostat. Regular ECGs should be obtained during treatment, and electrolytes should be monitored and corrected as needed.
Myelosuppression: Farydak 20 mg capsules can cause myelosuppression, leading to severe thrombocytopenia, neutropenia, and anemia. Complete blood counts (CBC) should be obtained and monitored weekly during therapy, or more frequently if clinically indicated. Patients over 65 years should have their CBCs monitored more often due to a higher risk of myelosuppression.
Infections: Patients taking Farydak, including the 10 mg dosage, may develop localized and systemic infections such as bacterial infections, pneumonia, invasive fungal infections, and viral infections. Monitor for signs and symptoms of infection during therapy. If an infection is diagnosed, initiate appropriate anti-infective treatment promptly and consider interrupting or discontinuing Farydak.
Liver Dysfunction: Hepatic dysfunction, including elevated aminotransferases and total bilirubin, has been observed in patients treated with panobinostat. Liver function should be monitored before starting treatment and regularly throughout the therapy.
Pregnancy Risks: Panobinostat can cause fetal harm if used during pregnancy. It has been shown to be teratogenic in animal studies with rats and rabbits. If a patient becomes pregnant while taking this drug, they should be informed of the potential risks to the fetus.
Documentation Availability
Documents required to import FARYDAK to India?
FARYDAK (panobinostat) capsules can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing FARYDAK (Cancer Treatment Medicines) around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for Farydak®?
The generic name for Farydak® is panobinostat.
Is Farydak® FDA Approved?
Yes, Farydak® was approved by the FDA on February 23, 2015.
What Should I Avoid While Taking Farydak®?
Avoid consuming star fruit, pomegranate or pomegranate juice, and grapefruit or grapefruit juice, as these can affect the blood levels of Farydak®.
What Dosage Forms and Strengths are Available for Farydak®?
Farydak® is available in capsule form, with strengths of 10 mg, 15 mg, and 20 mg for oral administration.
What are the Common Side Effects of Farydak®?
Common side effects include nausea, diarrhea, fatigue, peripheral edema, decreased appetite, vomiting, and fever.
What are the Storage Conditions for Farydak®?
Store Farydak® at 20°C to 25°C (68°F to 77°F). Keep the blister packs in the original carton to protect them from light.
How to order Farydak® online in India?
Farydak® can be ordered online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
